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Abstract
Overproduction of amyloid-b (Ab) protein in the brain has been hypothesized as the primary toxic insult that, via numerous
mechanisms, produces cognitive deficits in Alzheimer’s disease (AD). Cholinesterase inhibition is a primary strategy for
treatment of AD, and specific compounds of this class have previously been demonstrated to influence Ab precursor
protein (APP) processing and Ab production. However, little information is available on the effects of rivastigmine, a dual
acetylcholinesterase and butyrylcholinesterase inhibitor, on APP processing. As this drug is currently used to treat AD,
characterization of its various activities is important to optimize its clinical utility. We have previously shown that
rivastigmine can preserve or enhance neuronal and synaptic terminal markers in degenerating primary embryonic
cerebrocortical cultures. Given previous reports on the effects of APP and Ab on synapses, regulation of APP processing
represents a plausible mechanism for the synaptic effects of rivastigmine. To test this hypothesis, we treated degenerating
primary cultures with rivastigmine and measured secreted APP (sAPP) and Ab. Rivastigmine treatment increased metabolic
activity in these cultured cells, and elevated APP secretion. Analysis of the two major forms of APP secreted by these
cultures, attributed to neurons or glia based on molecular weight showed that rivastigmine treatment significantly
increased neuronal relative to glial secreted APP. Furthermore, rivastigmine treatment increased a-secretase cleaved sAPPa
and decreased Ab secretion, suggesting a therapeutic mechanism wherein rivastigmine alters the relative activities of the
secretase pathways. Assessment of sAPP levels in rodent CSF following once daily rivastigmine administration for 21 days
confirmed that elevated levels of APP in cell culture translated in vivo. Taken together, rivastigmine treatment enhances
neuronal sAPP and shifts APP processing toward the a-secretase pathway in degenerating neuronal cultures, which mirrors
the trend of synaptic proteins, and metabolic activity.
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Introduction
Alzheimer’s disease (AD) is the most common cause of dementia
in the elderly, afflicting approximately 5.4 million people in the
United States [1] with steady increases projected to at least mid-
century as the current population gradually ages [2]. AD is a
mutifactorial disorder with an unclear etiology. Some of the
potential causative or contributing factors implicated in AD
include genetic and epigenetic factors [3,4], diet and physical
activity [5], education [6], heavy metal exposure [7], and other
gene-environment interactions [8]. Psychological attributes of the
individual, such as a subjective sense of a purposeful life, may also
correlate with risk of developing AD [9].
AD is diagnosed post mortem based on the presence in brain of
amyloid plaques, comprised mostly of amyloid-b (Ab) peptides,
and neurofibrillary tangles (NFTs) of hyperphosphorylated
microtubule associated protein tau (MAPT). Ab, together with
other proteolytic fragments of dysregulated amyloid precursor
protein (APP) processing, have been implicated as major mediators
of neurotoxicity in AD [10] and are known to induce toxic effects
through a wide variety of mechanisms.
One important therapeutic goal in AD treatment is to restrict
the progression and/or delay the onset of the disease. Currently,
the cholinesterase inhibitors (ChEI) tacrine, donepezil, rivastig-
mine, galantamine and a partial NMDA receptor antagonist
memantine are the only drugs approved by the FDA for treatment
of AD [11,12]. The main aim of ChEI treatment is to inhibit
enzymatic degradation of the neurotransmitter acetylcholine,
resulting in an increased amount of acetylcholine in the synaptic
terminals [13,14]. Memantine is thought to protect neurons from
glutamate induced excitatory damage [15], and may also
modulate Ab production [16]. However, the aforementioned
FDA approved drugs do not adequately restrict or reverse the
progression of AD. Therefore, several different approaches, such
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22as regulating levels of Ab precursor protein (APP) by novel
microRNA mediated mechanisms, are under investigation [17].
APP is a type I transmembrane protein that undergoes
proteolytic processing by secretase enzymes to generate soluble
fragments [18]. Through alternative splicing, APP is generated in
several different forms in various tissues throughout the body. In
the brain these range from 695 to 770 amino acids, based on
alternative splicing of the Kunitz protease inhibitor domain (KPI)
and MRC OX-2 antigen (OX-2) domains [19]. Previous work has
suggested that the longer KPI-containing APP is produced mainly
by gilal cells, while the shorter non-KPI containing splice variant is
primarily or neuronal origin [20]. Furthermore, there is evidence
that a shift in APP isoforms favoring production of KPI-containing
APP may contribute to amyloidogenesis [21]. Sequential cleavage
of APP by b-secretase (BACE1) and the c-secretase complex
produces sAPPb and Ab peptide, the major component of amyloid
plaques found in AD [22]. Non-amyloidogenic cleavage by a-
secretase and c-secretase releases the carboxyl-truncated secreted
sAPPa and non-amyloidogenic 3 kDa peptide (p3), instead of
intact 4 kDa Ab [22]. Notably, the predominant sAPPa species
has been shown to exhibit a wide array of neurotrophic activities
[23,24], which are important for neuron development and
survival. We postulate that elevated levels of sAPPa could
participate in cellular metabolic activity, enhancing neuron
survival under pathological conditions such as AD.
Contrary to sAPPa, higher levels of Ab are known to be toxic. It
has been reported that ganglioside-bound Ab initiates Ab
aggregation by acting as a seed [25], which could lead to
aggregation states with enhanced toxicity. Ab derived diffusible
ligands (ADDLs) are soluble multimers of Ab that are thought to
be the predominant source of Ab-mediated toxicity in the AD
brain [26]. Another important mechanism of Ab toxicity that is
particularly pertinent to memory impairment is a reduction in
functional synapses [27]. Synapse loss is not part of the definitive
criteria required for AD diagnosis, however, it has been
consistently found that synapse density may correlate more closely
with the clinical manifestations of AD than plaque or NFT density
[28], and occurs early in the course of AD [29]. Recent evidence
suggests that secreted APP (sAPP) is protective against neuronal
apoptosis [30], and thus may mitigate some of the toxic events that
occur in the AD brain.
We have recently demonstrated that rivastigmine (Exelon
tm,
Novartis), a dual acetyl- and butyrylcholinesterase inhibitor, can
preserve neuronal morphology as well as pre-synaptic protein
markers in our degenerating primary neuronal culture model [31].
Rivastigmine is a novel intermediate-acting reversible non-
competitive carbamate dual acetyl- and butyryl-cholinesterase
inhibitor which is currently used for the treatment of AD [32],
however, its mode of action is incompletely understood. Others
have shown that sAPP can prevent neurite retraction in response
to proteasome stress [33]. Herein, we test the hypothesis that the
effects of rivastigmine on synaptic protein levels, neuronal
morphology, and metabolic activities may be mediated, in part,
by modulation of APP processing and metabolic activity of the
cells. Rivastigmine is an established therapeutic agent used to treat
AD, and a more complete understanding of its actions on neuronal
cells can be expected to both optimize its clinical potential and aid
future drug development efforts by providing new drug targets and
experimental endpoints. To this end, we treated degenerating
primary fetal rat cortical cell cultures with rivastigmine and
measured secretion of total APP, sAPPa, and Ab peptide and
compared these to levels of pre- and post-synaptic markers, and
metabolic activity. Rivastigmine treatment induced an elevation in
both metabolic activity and APP secretion, and differentially
impacted two isoforms of sAPP, which are distinguishable by
molecular weight. In our cultures, low molecular weight sAPP
corresponded closely to neuronal viability, and high molecular
weight sAPP corresponded with glial proliferation. Our results
suggest that within the mixed culture system used, neurons are the
primary source of sAPP, and rivastigmine’s actions are mediated
principally through neuronal, rather than glial, targets. Impor-
tantly, rivastigmine was found to increase the neurotrophic sAPPa
and decrease Ab secretion, suggesting a mechanism for the
previously observed neuropreservation effects. These changes in
APP processing were accompanied by increased pre- and post-
synaptic markers, suggesting a possible role for APP secretion in
the effects of rivastigmine. These findings were extended to an in
vivo model in which increased sAPP levels were found in the
cerebrospinal fluid (CSF) of rats treated with rivastigmine daily for
three weeks. Taken together, our results suggest that rivastigmine
treatment enhances neuronal sAPP in degenerating neuronal
cultures. This effect mirrors the trend of neuronal and synaptic
proteins, and cellular metabolic activity. Further, rivastigmine’s
effect was translated to in vivo studies in a wild-type animal strain.
Based on the results from our unique primary degenerating culture
model and separate in vivo studies, we suggest that rivastigmine’s
novel positive effect on neuronal viability would further help to
optimize this drug for the treatment of AD.
Materials and Methods
Ethics Statement
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee of Indiana
University, and conform to NIH guidelines (study #2872).
Primary embryonic rat cerebrocortical cultures
Primary embryonic rat cortical cultures were generated using
previously published procedures [34], with small modifications as
described previously [31]. Cerebrocortical tissue from embryonic
day 16 rat pups was collected and dissociated by trituration with a
fire-polished Pasteur pipette. Cells were seeded into 12-well tissue
culture treated, poly-D-lysine (Sigma-Aldrich, St. Louis, MO)
coated, polystyrene multiwell plates (Corning, Lowell, MA). Cells
were maintained in Neurobasal medium supplemented with B27
serum replacement, antibiotic cocktail, 5 ng/ml basic fibroblast
growth factor, 0.5 mM L-glutamine (Invitrogen, Carlsbad, CA),
and 16 Normocin (InVivoGen, San Diego, CA). Media were
changed every fourth day until day 14 when rivastigmine was
added during a final media change. Cells were treated until day 16
when media samples were collected and cells were removed from
the plate by scraping with a rubber-tipped spatula in Dulbecco’s
phosphate buffered saline (D-PBS; Invitrogen). Cells were pelleted
by centrifugation and lysed by sonication in lysis buffer containing
50 mM Tris-HCl (pH 7.0–7.5), 150 mM NaCl, 5 mM EDTA,
0.5% Triton X-100, 0.5% sodium deoxycholate (all from Sigma-
Aldrich) and 16 Complete Mini protease inhibitor cocktail
(Roche, Indianapolis, IN).
Characterization of an in vitro neurodegeneration model
Previous experience with cells cultured under the above
conditions suggests that the neurons in this mixed culture
degenerate with time while glia proliferate. This presents a
possible model for testing various drugs for potential neuropre-
servative effects. To more clearly define this model, samples were
taken at 12 days and 20 days in vitro and cell lysates were examined
by Western blot for levels of neuron-specific enolase (NSE), glial
fibrillary acidic protein (GFAP), and the conditioned media
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from the present manuscript should be considered in the context of
the effect of rivastigmine in the degenerating primary cerebrocor-
tical cultures and not in a static cell culture model.
Rivastigmine extraction from capsules
Rivastigmine was provided as a gift by Dr. Martin Farlow as
1.5 mg pharmaceutical capsules. The contents of the capsules
were dissolved in sterile water and disrupted by sonification, then
clarified by centrifugation to yield a 5 mM stock solution. Other
contents of the capsules included hydroxypropyl methylcellulose,
magnesium stearate, microcrystalline cellulose, and silicon dioxide,
and are generally considered as pharmaceutically inert [35]. The
concentration of this rivastigmine stock was subsequently con-
firmed by comparison to an analytical standard (provided by
Novartis) by UV-Vis spectrometry using a Nanodrop spectropho-
tometer (Thermo Scientific, Waltham, MA).
Drug treatment conditions
In the cell culture experiments, rivastigmine treatments were
performed by adding the 5 mM stock solution of capsule-extracted
drug in to the Neurobasal based growth medium described above
at the concentrations indicated in the figures. In all experiments,
untreated or ‘‘vehicle treated’’ cells were included for comparison
to the rivastigmine-treated cells.
ATP-based metabolic activity assessment
Relative ATP concentrations were measured using the lucifer-
ase based Cell Titer-Glo kit (CTG; Promega, Madison, WI), as
described previously [16]. After treatment, cells were rinsed once
in cold PBS and then collected by scraping with a rubber-tipped
spatula. Thirty microliter aliquots of these cell suspensions in D-
PBS were transferred to an opaque white 96-well plate (Corning,
Lowell, MA) and 30 ul of the CTG assay solution was added and
the plate was placed on an orbital shaker for 10 minutes to induce
lysis of the cells. The luminescent signal was quantified using a
Glowmax luminometer (Promega).
Lactate dehydrogenase-based toxicity assay
Cells were monitored for toxic effects of rivastigmine treatment
using a commercially available lactate dehydrogenase (LDH)
based kit (Sigma-Aldrich). The LDH enzyme is a cytosolic
component of the glycolytic pathyway, and leakage from the
cytoplasm into the cell culture medium is an indication of
membrane permeability, which results from cellular toxicity. At
the conclusion of an experiment, 30 ml aliquots of the conditioned
medium were assayed from each well. LDH concentration in the
media samples was calculated by comparison to standards of
known LDH content (Roche).
Western immunoblotting
Relative APP protein levels were examined in media samples of
rivastigmine treated cells by standard Western blot with
immunodetection techniques, as described previously [16]. Briefly,
media samples were resolved under SDS-induced denaturing
conditions on 15-lane, 10% polyacrylamide gel using the Mini
Protean II system for larger sample volumes, or on 10%
polyacrylamide 26-lane Criterion-XT gels for larger sample
numbers (Bio-Rad, Hercules, CA) then transferred to 0.2 mm
poresize PVDF. Blots were probed with monoclonal mouse-anti-
APP (22C11; Millipore, Billerica, MA), polyclonal rabbit-anti-KPI
(KPI; Abcam, Cambridge, MA) to detect long splice variant APP
KPI, and monoclonal mouse-anti-b-actin (Sigma-Aldrich) as an
internal control. The blots were then probed with the appropriate
horseradish peroxidase-conjugated secondary antibody (Pierce,
Rockford, IL) and detected by ECL techniques (GE Healthcare,
Piscataway, NJ).
To detect proteins found in the lysates of cultured cells, protein
concentrations of the lysates were determined by the Bradford
technique (BioRad), and 10 mg of each lysate protein was
subjected to electrophoresis and Western blotting under conditions
identical to the media samples. Blots of the lysates were probed
with mouse-anti-SNAP-25 (Millipore), mouse-anti-PSD-95 (Anti-
bodies Incorporated, Davis, CA), mouse-anti-syntaxin-4 (BD
Transduction Labs, Franklin Lakes, NJ), mouse anti-b-actin
(Sigma-Aldrich), and the 22C11 antibody as above, followed by
the appropriate secondary antibody and ECL detection.
Enzyme linked immunosorbent assays (ELISAs)
Measurement of a-secretase cleaved secreted APP (sAPPa)i n
the conditioned medium (CM) was undertaken by by a sensitive
and specific ELISA (IBL, Gumma, Japan). The assay was
performed per manufacturer’s protocol. Briefly, 30 mlo fC M
samples were loaded in capture antibody (anti rodent APP; clone
597) coated wells of the ELISA plate and incubated overnight at
4uC. After several washes the wells were incubated with detection
antibody (HRP-conjugated anti rodent. APP; clone 18) for 30 min
at 4uC. After additional washes, chromogen solution was added
into each well and kept at room temperature for 30 min. The
reaction was stopped by adding 1N H2SO4 and colorimetric
signals were recorded (450 nm) using a Model 550 microplate
reader (BioRad). A standard curve with known amounts of
recombinant rodent sAPPa was also generated. sAPPa values were
normalized by the total protein content of the CM samples and
plotted as pg/mg of protein present in CM samples.
Measurement of Abx-40 in the CM samples was carried out by
using a sensitive chemiluminescence ELISA (Covance , Prince-
ton, NJ) as described previously [36]. Chemiluminescence signals
were normalized by the total protein content of CM samples to
obtain pg of Abx-40 present in per mg of protein of CM samples.
This Ab ELISA kit detects full length sequence of Ab1–40 and
also peptides generated by N-terminal cleavage of APP, such as
Ab3–40,A b11–40 etc.
Immunocytochemistry
Cultures were maintained until day 12 or day 20 and then
rinsed once in Dulbecco’s phosphate buffered saline (DPBS;
Invitrogen, Carlsbad, CA) and fixed in the cell culture plate with
4% paraformaldehyde. Cells were then permeabilized with 0.5%
Triton X-100 (Sigma) and non-specific binding was blocked with
10% horse serum (Atlanta Biologicals, Lawerenceville, GA).
Mouse anti-MAP2 (Abcam) followed by a biotinylated donkey-
anti-mouse secondary antibody and FITC-conjugated streptavidin
(Jackson IR, West Grove, PA) or rabbit anti-GFAP (Sigma-
Aldrich) followed by Cy3 conjugated donkey-anti-rabbit secondary
antibody (Jackson IR). Cells were visualized using a Leica DM-IL
inverted microscope (Wetzlar, Germany) fitted with a SPOT RT-
SE camera (Diagnostic Instruments, Sterling Heights, MI). These
time points were selected because our previous observations of
these cultures indicated that neuronal morphology peaked around
day 12, and by day 20, the neuronal population subsided and glia
had become prominent (unpublished observations).
Study of rivastigmine effects on sAPP in vivo
Male Fischer-344 rats, weighing approximately 200 g (Harlan,
Indianapolis, IN), were separated into groups of 8–12 animals and
treated for 21 days with either rivastigmine (0.75 mg/kg i.p.,
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saline only). In addition, a separate group was administered
phenserine tartrate (2.5 mg/kg i.p., in 1 ml/kg isotonic saline) as a
positive control, as this compound has been consistently reported
to lower the rate of APP synthesis and APP levels in the brain [37].
Thereafter, rats were killed within 90 to 120 min of their final
dosing and CSF was immediately obtained from the cisterna
magna, and frozen at 270uC until assayed for sAPP levels.
Levels of total sAPP in CSF samples (5 ml) were assayed by
Western immunoblot analysis as previously described [16] and
probed with anti-APP antibody, 22C11. This recognizes all forms
of APP in CSF, as well as the APP-like proteins (APLP). The
former migrated as two bands (110–130 kDa), whereas the latter
migrated at a slightly different rate, to (70 kDa), and were not
quantitated.
Data analysis
Western blot data (ECL films) were scanned and quantified
using ImageJ software [38]. Statistical analysis was performed
using one-way ANOVA with Tukey post-hoc test (SPSS
s o f t w a r e ,v .1 7 ) .Ap - v a l u eo f,0.05 was considered statistically
significant.
Results
Development of a neurodegenerating model of primary
cerebrocortical cultures: Transition of cell types and sAPP
isoforms over time
To examine the sources of sAPP in the conditioned media of
these cultures, media and lysate samples from cells maintained for
12 days or 20 days in vitro were compared by Western blotting and
immunocytochemistry techniques (figures 1 and 2). We have
observed that the neuronal component of these mixed primary
cultures peaked around day 12, as confirmed by the presence of
NSE in the lysates (figure 1A) and robust neuronal morphology
observed by MAP2 immunocytochemistry (figure 2). Simulta-
neously, the glial component began to increase around day 12, as
observed by the presence of GFAP by Western blot and
Figure 1. Establishment of a neurodegenerating model of primary cerebrocortical cultures: Association of different APP isoforms
with glial and neuronal cell types. A: Cell lysates and conditioned media samples of primary cortical cultures were collected at day 12 and day 20
for Western blot analysis. At day 12 compared to day 20, levels of the neuronal marker NSE are high, and levels of the glial marker GFAP are low. This
indicates that at day 12 the neuronal population is intact, whereas the glial population becomes more pronounced at day 20, and neurons have
degenerated by day 20. In the sAPP blot, reduced levels of low molecular weight sAPP coincide with the loss of neurons, while the increased high
molecular weight sAPP parallels the increase in glia abundance. Approximate molecular weights are indicated. Day 12 and day 20 samples were
examined on the same blots with irrelevant samples cropped from the images. B: A detailed view of sAPP bands in single representative lanes of
Western blots from neuron-rich (day 12) and glia-rich (day 20) cell cultures reveals that the lower band (,110 kDa) is predominant over the upper
band (,130 kDa) in neuron-rich cultures This pattern is reversed in glia-rich cultures, with a predominant upper band, and very little sAPP present at
the lower molecular weight. C: Densitometric quantification of the top vs. bottom bands from day 12 and day 20 samples is also shown. Levels of the
high molecular weight top band are relatively stable with time, while levels of the low molecular weight bottom band decrease dramatically between
day 12 and day 20, concurrent with neurodegeneration.
doi:10.1371/journal.pone.0021954.g001
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lysates and very little MAP2 was visualized by immunocytochem-
istry, indicating that the neuronal component is almost completely
absent. At day 20, greatly increased GFAP was observed by both
Western blot and immunocytochemistry. Please note that all
samples comparing cell type markers at different time points were
run in the same gel with irrelevant (e.g., other drug treatments)
cropped out for clarity. When compared to the relative intensities
of the two major sAPP bands, the low molecular weight band was
very strong at day 12, and appeared to associate with the neuronal
component. The high molecular weight band was more prominent
at day 20 when the glial component had become prominent
(figure 1B). The levels of APP holoprotein (hAPP) in the cell lysates
during this time was also reduced and shifted toward higher
molecular weight forms (figure 1A).
Rivastigmine treatment increased metabolic activity and
preserved neuronal viability
Cell viability and metabolic activity as measured by the CTG
assay increased dose-dependently at 5 mM, 10 mM and 20 mM
rivastigmine but not 2 mM (figure 3B). While this is a mixed
culture and effects on glial cells cannot be ruled out completely,
data presented here (figure 3a), as well as previously reported data
[31], suggest that the observed increase in viability is primarily due
to preservation of neurons. LDH release from the cells was not
affected by any concentration of rivastigmine tested, indicating no
toxicity.
Rivastigmine treatment preserved neuronal structure
This model of degenerating primary neurons was then applied
to examine the preservative effect of rivastigmine on neuron
Figure 2. Rivastigmine preserves neuronal morphology and alters sAPP secretion. A: At day 12 or day 20, cells were fixed for
immunocytochemistry analysis and probed with anti-MAP2 (green) and anti-GFAP (red) antibodies. Neuronal MAP2 immunoreactivity declines to
almost undetectable levels between day 12 and day 20 in untreated cells, whereas neuronal morphology is preserved in rivastigmine treated cultures.
Glial GFAP was observed to increase in both treated and untreated cells between day 12 and day 20. These results confirm the degeneration of
neurons by day 20. All samples were examined on the same blot with irrelevant samples cropped from the images. B: In a separate experiment,
media samples were taken before the onset of neurodegeneration at day 12 and during the degenerating phase of the cell culture at day 16. The
lower molecular weight neuronal form of sAPP declined significantly in untreated cells, but was rescued by 10 mM rivastigmine treatment.
doi:10.1371/journal.pone.0021954.g002
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treatment continued up to day 20 (figure 2A). The timing of this
treatment was designed to determine the effect of rivastigmine
during the period of neurodegeneration and glial proliferation
observed previously. Notably, rivastigmine treatment preserved
substantially, but not completely, neuronal structure during this
period. Thus, rivastigmine treatment protected neurons from
degeneration. In a separate experiment, sAPP was measured in the
conditioned media of cells treated with vehicle or rivastigmine
during the degenerating phase of the cell culture (figure 2B).
Relative to day 12, the lower band was markedly reduced in
vehicle treated cultures, while in rivastigmine treated cultures,
there were significantly greater levels of low molecular weight
sAPP. These results are consistent with a primarily neuronal
source for the low molecular weight sAPP band and a glial source
for the high molecular weight band as shown (figure 1). We further
determined that the difference in apparent molecular weight
represented by these two sAPP bands is the result of alternative
splicing (see figure 4, below).
Rivastigmine treatment increased the secretion of
neuronal-associated sAPP isoform
Western blot data show a statistically significant increase in total
sAPP secretion at 5 mMo r1 0mM rivastigmine treatments, relative
to vehicle (figure 4A; p,0.05). APP secreted from these cells
typically formed a major doublet of bands on Western blots. The
two major sAPP bands detected by the 22C11 antibody were
quantified individually and are presented as percent of the total
sAPP. Plotted this way, it is clear that the relative contribution of
these two bands to the total sAPP is divergent, in that the bottom
band increases and the top band decreases relative to the total with
rivastigmine treatment. We have observed that the top band
corresponds to longer splice variants of APP and tends to co-vary
with glial cell density, whereas the lower molecular weight band,
corresponding to shorter splice variants of sAPP, co-varies with
neuronal cell density (figures 1 and 2). This shift toward lower
molecular weight forms of sAPP suggests a stronger neuronal
contribution to sAPP secretion. The ratio between the two sAPP
bands was significantly shifted toward the low molecular weight
Figure 3. Rivastigmine enhances cell viability in neurodegenerating primary cultures. A: Rivastigmine is a parasympathomimetic
cholinergic agent used for the treatment of mild to moderate AD. Its systematic (IUPAC) name is (S)-N-Ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-
phenyl carbamate. B: Primary cultures were treated with rivastigmine at the indicated concentrations for 4 days starting at day 12, and were then
subjected to the Cell Titer-Glo (CTG) assay to assess cell viability and metabolic activity. Significant increases in ATP concentrations were observed in
the lysates of cells treated with 5 mM, 10 mM and 20 mM rivastigmine (both p,0.05), while no effect was observed with 2 mM rivastigmine. The
potential of drug-induced toxicity was assessed by measuring LDH release, but no significant difference from vehicle was observed, suggesting that
all rivastigmine doses were well tolerated.
doi:10.1371/journal.pone.0021954.g003
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treatment. This robust effect of rivastigmine on neuronal
associated sAPP parallels cellular metabolic activity in neurode-
generating primary fetal rat cortical cultures (figure 3).
Rivastigmine treatment had no effect on the level of KPI-
containing secreted APP
Alternate splicing of sAPP was assessed by Western blot
using an antibody specific to the KPI domain of the longer 751
and 770 amino acid APP isoforms (figure 4B). These data show
that the higher molecular weight (,130 kDa) of the two sAPP
bands detected by the 22C11 antibody contains the KPI
domain. Conversely, the lower (,110 kDa) molecular weight
band was not observed using the KPI-specific antibody. No
difference in the levels of KPI containing APP was observed
between vehicle and either concentration of rivastigmine.
Combined with the cell type marker data (figure 1), these data
suggest that the increase in total sAPP levels observed using the
22C11 antibody is produced principally by the neurons in
these cultures.
Rivastigmine shifts APP processing toward the
a-secretase pathway
ELISA analysis of media samples of rivastigmine-treated
cultures revealed a significant increase in sAPPa in both 5 mM
and 10 mM rivastigmine treatments (figure 5a; both p,0.01). In
the same samples, ELISA analysis also showed that Abx-40 was
significantly reduced (Figure 5b; both p,0.01). Together, these
results suggest that rivastigmine alters the activities of the a- and b-
secretase pathways in favor of sAPPa production. In both assays,
the 5 mM and 10 mM treatments do not differ significantly from
each other, suggesting a ceiling effect for these changes may occur
below 5 mM rivastigmine. Measurement of Abx-42 was also
attempted, but this was found to be below the limit of detection.
Rivastigmine treatment had no effect on levels of APP
holoprotein
To investigate effect of rivastigmine on APP gene expression,
the uncleaved APP holoprotein (hAPP) was measured in the lysates
of rivastigmine treated cells vs. vehicle treated control cultures. A
predominant single band corresponding to intracellular hAPP was
Figure 4. Rivastigmine increases the proportion of neuron-associated sAPP isoform to total secreted amyloid precursor protein
(sAPP). A: Relative levels of total sAPP were measured by Western blot using the monoclonal 22C11 antibody. Densitometric quantification of the
blots indicates that total sAPP is increased significantly at both rivastigmine concentrations tested (both p,0.05). The intensity of each band relative
to the total sAPP was calculated and the top and bottom bands show diverging patterns, with the top band decreasing with rivastigmine treatment,
and the bottom band increasing with rivastigmine treatment relative to total sAPP. B: Levels of the longer KPI-containing sAPP isoform were
determined by Western blot using a KPI-specific antibody. A single band was detected in the media samples of these cells, and the molecular weight
of this band coincides with the higher molecular weight band detected with the 22C11 antibody. Thus, the distinguishing characteristic between the
top and bottom bands observed with 22C11 are differences in splicing. Levels of KPI containing APP are not altered by rivastigmine treatment.
doi:10.1371/journal.pone.0021954.g004
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as a result of rivastigmine treatment as compared to vehicle
(figure 6). These results suggest no change in total APP production
in these cultures as a result of rivastigmine treatment, or perhaps a
modest increase if APP holoprotein is combined with sAPP. A
direct comparison cannot be made with the techniques applied
here, though the potential effect of rivastigmine on total expression
of APP may warrant further study.
Rivastigmine-mediated increase in neuron-associated
sAPP parallels elevations in synaptic protein markers
In neurodegenerating primary fetal rat cerebrocortical cul-
tures, significant increases in the pre-synaptic marker SNAP-25
and the post-synaptic marker PSD-95 were observed with 10 mM
rivastigmine treatment (both p,0.05). A second pre-synaptic
marker, syntaxin-4 was also increased by about two-fold
compared to vehicle, but this effect did not reach significance
(figure 7A and 7B). sAPPa (reproduced from figure 5 for
comparison) increased dramatically with rivastigmine treatment,
which follows the increasing patterns of synaptic markers and cell
viability (figure 7B). Low molecular weight sAPP was increased
significantly (p,0.05) by both concentrations of rivastigmine,
while a smaller, but statistically significant, increase in high
molecular weight sAPP was observed at 5 mM, but not 10 mM
rivastigmine (figure 7C). These data suggest a differential
involvement of these sAPP isoforms in the response to
rivastigmine and synapse preservation.
Rivastimine treatment increased levels of secreted APP in
rat CSF samples
To elucidate whether drug-induced changes in APP levels
determined in tissue culture translated to animals, male Fischer-
344 rats were separated into groups of 8–12 animals and treated
for 21 days with either rivastigmine (0.75 mg/kg i.p., prepared in
1 ml/kg volume isotonic saline) or vehicle (isotonic saline only) as
described in ‘Materials & Methods’. All groups of treated rats
gained weight in a manner similar to controls (data not shown),
and there were no signs of drug-related toxicity. The presence of
secreted total sAPP was detected in rat CSF samples by Western
blot analysis. Densitometeric analysis revealed that rivastigmine
(0.75 mg/kg for 21 days) significantly elevated CSF levels of sAPP
to 154%68.1 of saline controls (100%613,7), whereas the
positive control, phenserine (2.5 mg/kg for 21 days), reduced
sAPP levels to 57.9%67.4 (p,0.05 vs. control for both
treatments; figure 8).
Figure 5. Rivastigmine shifts APP processing toward the a-secretase pathwayI. Levels of sAPPa and Abx-40 were measured in media
samples of cultures treated with rivastigmine using ELISA techniques. A: sAPPa increased significantly in response to both 5 mM and 10 mM
rivastigmine (both p,0.01), but the treatments were not significantly different rom each other suggesting a maximum effect of rivastigmine at or
below 5 mM. B: Abx-40 levels were decreased by both concentrations of rivastigmine (both p,0.01). This effect was also not dose-dependent,
suggesting a maximum effect at 5 mM or lower concentrations. Together, these data suggest a shift in the relative activities of the a- and b-secretase
pathways, favoring production of the neurotrophic a-secretase product sAPPa while simultaneously reducing the neurotoxic b-secretase product Ab.
doi:10.1371/journal.pone.0021954.g005
Figure 6. Rivastigmine does not alter APP holoprotein. APP
levels in lysates of cerebrocortical cultures treated with vehicle or
rivastigmine were measured by Western blot using the 22C11 antibody.
No difference in APP holoprotein was found in either the 5 mMo r
10 mM rivastigmine treatments, indicating that changes in sAPP levels
are not the result of changes in total APP production in these cells.
doi:10.1371/journal.pone.0021954.g006
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One major current goal for AD treatment is to restrict the
progression and/or delay the onset of the disease. The currently
available therapies based on ChEI or NMDA receptor antagonist
treatments have failed to adequately attain this goal. Thus, a
variety of alternate strategies are being pursued [11], including
microRNA based mechanisms [39] and modulation of inflamma-
tory processes [12,40]. Secretion of APP through secretase-
mediated cleavage has been a major focus of AD research due
to the numerous possible roles of sAPP and the potentially toxic
effects of the Ab peptide. In fact, secreted products of APP and Ab
have been extensively studied to understand the molecular
pathogenesis of AD as well as to target them for the development
of suitable therapeutic agents. Indeed, a small, orally available
naturally occurring compound, scillo-inositol, has been shown to
penetrate into the brain and to rescue the memory impairment
produced by soluble Ab oligomers in animal models through a
mechanism that restores hippocampal synaptic plasticity [41].
This promising compound is currently under investigation in
early-stage clinical trials, but will require several years of additional
investigations if it is to become widely available.
With regard to APP, it has been demonstrated previously that
certain cholinesterase inhibitors can modulate APP secretion both
in cell cultures and in vivo [42] . For example, the ChEI tacrine
regulates sAPP levels in a variety of neuronal, glial and other cell
types, but another ChEI, physostigmine, does not [43–45]. In
experiments comparing the ChEIs physostigmine and phenserine,
which are very similar in structure and potency for cholinesterase
inhibition, differing effects on APP processing were observed [46].
This again suggests that changes in APP processing may involve
mechanisms beyond those mediated by the cholinergic system.
While the exact mechanism of action for most ChEIs are unclear,
data suggesting mechanisms of action for certain ChEIs are
available [47]. Therefore, this class of drugs represents a potential
means, if appropriately optimized and translated, for modifying
the course of AD by mitigating the downstream effects of Ab, such
as synapse loss. To this end, we have characterized the effects of
the dual acetyl- and butyrylcholinesterase inhibitor, rivastigmine,
on synaptic markers and APP cleavage in degenerating primary
neuronal cultures.
We initially investigated the nature of the two most prominent
forms of APP secreted from these neuronal cultures. Previous work
has suggested that there is a time-dependent increase in neuronal
Figure 7. Rivastigmine-mediated increase in neuron-associated sAPP and sAPPa parallels increases in neuronal protein markers.
Levels of low molecular weight neuronal sAPP (LMW-sAPP), high molecular weight glial sAPP (HMW-sAPP), and sAPPa were compared to levels of the
presynaptic protein markers SNAP-25 and syntaxin-4, and the postsynaptic protein marker PSD-95. All values are expressed as a % of vehicle-treated
cells for comparison. PSD-95 and SNAP-25 levels increased dose-dependently with rivastigmine treatment (both p,0.05), and syntaxin-4 levels
increased but this change did not reach significance (7A and 7B). LMW-sAPP was increased with 5 mM rivastigmine but plateaued at the higher
concentration. HMW-sAPP increased to a lesser extent at 5 mM, but was similar to vehicle at the higher concentration (7C). These data suggest that
increased neuronal and decreased glial sAPP may be involved in the enhanced neuronal and synaptic marker stability that results from rivastigmine
treatment, and that modulation of a-secretase may be involved in these effects.
doi:10.1371/journal.pone.0021954.g007
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increased abundance of glial protein markers. Thus, we used the
duration of the primary cell culture to obtain samples with peak
neuronal marker expression (which occurs around day 12) and
longer duration cultures with predominant glial markers. We
confirmed by Western blot that samples taken at day 12, as
compared to day 20, were enriched in neuronal protein, whereas
the longer duration cultures were enriched in glial protein. The
relative neuronal and glial populations of this mixed culture were
also confirmed by immunocytochemistry. Our results contrast
somewhat with other reported data using similar primary culture
techniques. While our cultures begin to show glial activation and
neurodegeneration around two weeks in vitro, others have
reported viable neurons with limited glial activation for much
longer periods. For example, using the same Neurobasal plus B27
media system, Brewer et al., observed healthy neurons and few
activated glia at 4 weeks in culture [48]. The important differences
between our technique and others that report longer-lived
neuronal cultures include the use of mitotic inhibitors to prevent
glial proliferation, use of neurons from later-stage embryonic
animals, and refreshing only half the medium at a time. Our
deviations from these alternative protocols induce time-dependent
glial activation that results in neurodegeneration that is accompa-
nied by a shift in the APP produced in these cultures.
These results are in agreement with previous observations that
the KPI-containing APP is preferentially produced by cultured
astrocytes, and only produced at much lower levels in primary
neuronal cultures depeleted of glial cells [49]. Our results further
demonstrate that this preferential expression of APP splice variants
is maintained in cultures of mixed glial and neuronal cells. This
lends additional interest to this cell culture model, given that a
similar shift in APP isoforms, away from APP695 towards KPI-
containing APP (i.e., from lower to higher moleculear weight
forms of APP) has been observed in the cortices of AD-affected
brains. Such a shift was also accompanied by increased levels of
GFAP and Ab, which suggests that glial activation and changes in
APP isoforms are upstream events leading to AD pathology [50],
and is partially recapitulated in this model. This shift in APP
isoforms can be induced in animals by excitotoxic damage, and
prevented by neuroprotective agents [51], suggesting that reversal
of the shift from APP695 to KPI-containing APP may be an
important indicator of neuroprotection. In the cell lysates, total
levels of hAPP were not affected by rivastigmine treatment, thus it
appears that the effect of rivastigmine on sAPP is related to altered
processing rather than increased synthesis of APP. These findings
are interesting both with respect to the effect of rivastigmine, and
to future applications of this primary cell culture model.
Rivastigmine treatment increased the neuron-related low molec-
ular weight form of sAPP. This is suggestive of a mechanism by
which rivastigmine may protect neurons by enhancing sAPP
production, which may protect neurons from neurite retraction
[33] and apoptosis [30]. And, with regard to the culture model,
relative levels of these two major forms of sAPP could be used as
indicators of neuronal viability in a variety of situations, for
example, testing potential therapeutic agents.
We also investigated the relative activities of the a- and b-
secretase mediated pathways by observing the APP processing
products released into the medium by these cultured cells. We
observed a simultaneous increase in the a-secretase product
sAPPa, and a decrease in the b-secretase product Ab. Given the
neurotoxic nature of Ab [26,27] and the neurotrophic actions of
sAPPa [52], this shift in the relative activities of the secretase
pathways represents a likely mechanism for the neuroprotective
effects of rivastigmine. These effects on Ab and sAPP are not
observed by all cholinesterase inhibiting drugs [42,45], whiceh
raises the possibility of non-cholinergic effects of rivastigmine in
addition to the established acetylcholine-mediated actions. Further
elucidation of alternate mechanisms of this and other drugs may
provide new targets based on which better therapeutic agents can
be developed.
Efforts are currently underway to combine the therapeutic
potential of rivastigmine with that of the neuroprotective
monoamine oxidase-B (MAO-B) inhibitor rasagiline. The addition
of a carbamate group to rasagiline produced a molecule,
designated TV3326, that is a structural hybrid of rivastigmine
and rasagiline, and possesses both MAO-B and cholinesterase
inhibiting properties [53]. This compound may act, at least in
part, through activation of the PKC pathway [54]. Interestingly,
the compound TV3279, which is a stereoisomer of TB3326 which
does not inhibit MAO-B, has proven to be equally effective as the
‘‘active’’ compound in several paradigms. For example, both
stereoisomers provided similar stimulation of the neurotrophic a-
secretase pathway [54] and both provided greater protection from
oxygen-glucose deprivation than rivastigmine [55]. These studies
indicate that further mechanistic study and refinement of
rivastigmine, and perhaps other neuroprotective agents, could be
a fruitful strategy for producing the next generation of therapeutics
to treat AD.
We report here that rivastigmine treated primary cultures have
increased metabolic activity relative to untreated cells. We have
also recently reported, and confirmed here, that presynaptic
markers and neurite extension are increased by rivastigmine
treatment [31]. Additionally, we show that rivastigmine also
preserved the post-synaptic marker PSD95 in degenerating
neurons. This hints that not only is the axonal exocytotic
machinery preserved in rivastigmine-treated neurons, but so is
the dendritic post-synaptic component of the neuron. We also
Figure 8. Rivastigmine elevates CSF sAPP levels in rodents.
Separate groups of Fischer-344 male rats (n=8–12) were administered
saline (control) or rivastigmine (0.75 mg/kg) i.p. once daily for 21 days,
and CSF was collected within 120 min of the final dose for
quantification of sAPP by Western blot analysis probing with anti-APP
antibody, 22C11. The APP synthesis inhibitor, phenserine (2.5 mg/kg,
i.p. for 21 days) was administered to a concurrent group of animals as a
positive control (*,0.05 vs control, Dunnett’s t-test).
doi:10.1371/journal.pone.0021954.g008
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approximately two-fold increase with rivastigmine treatment,
although this was much smaller than the increases in PSD-95
and SNAP-25, and did not reach statistical significance. In
addition to neurons, syntaxin-4 was observed to be present at some
level in astrocytic cells while SNAP-25 was not [56], which may
explain the relatively higher levels of this protein in untreated
cultures as compared to the other synaptic markers measured.
Reductions in both pre- and post-synaptic proteins have been
observed in AD and these losses correlate strongly with cognitive
decline [57,58]. Thus, a drug that can restore these synaptic
markers may be useful in the treatment of AD. To this end, further
study of these effects of rivastigmine are warranted, especially with
respect to the shift toward a-secretase processing APP observed
here, and its potential role in synaptic and neuronal preservation
[52].
There are also interesting parallels between our cell viability
results and published in vivo data collected in AD patients treated
with rivastigmine. It was observed using positron emission
tomography (PET) techniques that cerebral glucose metabolism
declined in untreated AD patients, whereas glucose metabolism in
rivastigmine-treated subjects was stabilized. These differences also
correlated with cognitive performance [59]. In addition using PET
techniques, nicotinic binding was observed to increase in
rivastigmine treated subjects, which may represent a remodeling
of cholinergic networks [60]. These similarities support the use of
this kind of degenerating primary culture model to investigate AD
drugs and drug candidates in vitro.
To assess whether the actions of rivastigmine in cell culture
translated to animals, rivastigmine was administered to rats at a
dose previously reported to induce brain cholinesterase inhibition
[61], improve cognitive performance [62] and ameliorate
inflammation without toxicity [63] . As assessed in CSF,
rivastigmine significantly elevated sAPP levels by 154% compared
to control. This contrasted with phenserine, likewise a carbamate
type anticholinesterase, that has been reported to lower the rate of
synthesis of APP in the brain. This compound was used as a
positive control, which reduced CSF sAPP levels by 42.1%. This
increase in sAPP in animals suggests the hypothesis that similar
APP modulating and neuroprotective effects reported here may
also occur in rivastigmine-treated animals. Brain hypometabolism
has been established in AD, both as a correlate of reduced
cognitive function [64] and a predictor of cognitive decline in the
transition from mild cognitive impairment to AD [65]. Albeit that
definitive diagnosis of AD is dependent on the presence of amyloid
plaques and NFTs, synapse loss and neuronal atrophy, especially
in the medial temporal lobes, correlates well with cognitive decline
[28]. It is tempting to speculate that the hypometabolism
detectable by PET is linked directly to Ab-induced synapse loss
in the AD brain, but this remains to be shown. To the extent that
the action of rivastigmine in vivo is mirrored in this cell culture
model, these results have interesting implications, both with
respect to pharmacological treatment of AD, but also APP
metabolism and function.
In summary, our goal has been to study the effect of
rivastigmine on neuropreservation using a novel neurodegenerat-
ing primary rat cerebrocortical culture system [31]. The present
work assumes significance as this demonstrates that specific sAPP
isoforms, distinguishable by molecular weight, can be related to
neuronal or glial sources, and that rivastigmine treatment
enhances neuronal sAPP in degenerating neuronal cultures. This
effect mirrors the trend of neuronal and synaptic proteins, and
cellular viability. In addition, rivastigmine’s effect on total sAPP
levels was translated to in vivo studies in a wild-type animal strain.
In these rats, sAPP increased similarly to the in vitro model,
suggesting that the mechanism(s) of rivastigmine in vivo may also
involve increasing sAPP release. Additionally, the cholinesterase
inhibitor phenserine was shown to reduce sAPP in the CSF, which
suggests that different cholinesterase inhibitors act through
different mechanisms, which may include activities besides their
cholinesterase enzyme inhibiting activities.
The data presented here suggest that changes in metabolic
activity that result from rivastigmine treatment are associated with
increased neuronal survival, which is accompanied by changes in
the relative levels of the predominant isoforms of sAPP, and a shift
in the relative activities of the a- and b-secretase pathways. While
these data provide some insight into the mechanisms via which
rivastigmine acts on neurons, further experimentation should be
aimed at determining the effects of rivastigmine treatment on
neurons in order to guide future drug development efforts.
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